Crescentic, proliferative IgA nephropathy: Clinical and histological response to methylprednisolone and intravenous cyclophosphamide

Nephrology Dialysis Transplantation

Volumn 18, Issue 7, 2003, Pages 1321-1329

  Tumlin, James A ^a   Lohavichan, Verachai ^a   Hennigar, Randy ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Crescents; End stage renal disease; Endocapillary proliferation; Hypertension; IgA nephropathy; Proteinuria

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID;

ADULT; ARTICLE; CAPILLARY PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; MALE; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; SPINE FRACTURE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0037677136     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg081     Document Type: Article

References (18)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 2001; 64: 709-727
2. Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol 2000; 11: 2395-2403
3. Abe T, Kida H, Yshimura H, Koshino Y, Tomosugi N, Hattori N. Participation of extracapillary lesions (ECL) in progression of IgA nephropathy. Clin Nephrol 1986; 25: 37-41
4. Haas M. Histological subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29: 829-842
5. Ferrario F, Napodano P, Rastaldi M, D'Amico G. Capillaritis in IgA nephropathy. Contrib Nephrol 1995; 111: 8-12
6. D'Amico G, Napodano P, Ferrario F, Rastaldi MP, Arrigo G. Idiopathic IgA nephropathy with segmental necrotizing lesions of the capillary wall. Kidney Int 2001; 59: 692
7. Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC, Savino DA. Prognostic indicators in children with IgA nephropathy: report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 1994; 8: 15-20
8. Nicholls K, Walker R, Dowling J, Kincaid-Smith P. 'Malignant' IgA nephropathy. Am J Kidney Dis 1985; 5: 42-46
9. Welch TR, McAdams AJ, Berry A. Rapidly progressing IgA nephropathy. Am J Dis Child 1988; 142: 789-793
10. Subias R, Botey A, Darnell A, Montoliu J, Revert L. Malignant or accelerated hypertension in IgA nephropathy. Clin Nephrol 1987; 27: 1-7
11. D'Amico G, Minetti L, Ponticelli C et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 1986; 59: 363-378
12. D'Amico G. Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis 2001; 36: 227-237
13. Roccatello D, Ferro M, Cesano G et al. Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 2000; 15: 833-835
14. Pozzi C, Bolasco PG, Fogazzi G et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353: 883-887
15. Julian B. Treatment of IgA nephropathy. Semin Nephrol 2000; 20: 277-285
16. Lai K, Lai F, Ho C, Chan W. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986; 26: 174-180
17. Ballardie FW, Roberts ISD. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-148
18. McIntyre CW, Fluck RJ, Lambie SH. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescentic change: An effective treatment. Clin Nephrol 2001; 56: 193-198